PMID- 28082137
OWN - NLM
STAT- MEDLINE
DCOM- 20180409
LR  - 20211204
IS  - 2210-741X (Electronic)
IS  - 2210-7401 (Linking)
VI  - 41
IP  - 3
DP  - 2017 Jun
TI  - Sofosbuvir in combination with daclatasvir in liver transplant recipients with 
      HCV infection: A systematic review and meta-analysis.
PG  - 262-271
LID - S2210-7401(16)30207-8 [pii]
LID - 10.1016/j.clinre.2016.12.001 [doi]
AB  - BACKGROUND: Studies focusing on the efficacy of SOF+DCV regimen on liver 
      transplantation recipients with HCV infection are still limited. In the current 
      study, we aimed to perform a systematic review and meta-analysis to evaluate the 
      efficacy and tolerability of SOF+DCV regimen, with or without ribavirin, on 
      post-LT setting. METHODS: A systematic literature search of various databases as 
      well as abstracts of major liver diseases conferences was performed. Studies with 
      SVR data in HCV infected liver transplantation recipients treated with 
      daclatasvir/sofosbuvir regimen were included. All statistical analyses were 
      conducted by R version 3.3.1 (The R Foundation for Statistical Computing, Vienna, 
      Austria). RESULTS: Seven studies with a total of 379 LT recipients were included 
      in this study. Most of these LT recipients had genotype 1 HCV infection. The 
      overall rate of SVR12 reached 93.3% (95% CI: 83.3% to 99.4%). After excluding the 
      study of Fontana et al., the SVR12 reached 96.8% and heterogeneity was lowered 
      down (P=0.17). In three studies, patients treated with SOF+DCV (n=146) had a 
      higher SVR12 rate than that of patients treated with SOF+DCV+RBV (n=83) (OR 0.33, 
      95% CI: 0.12 to 0.87; P=0.02). There was no difference in SVR12 between patients 
      infected with HCV genotype 1 and genotype 3 (P=0.57) and no difference was found 
      in SVR12 rate between 12-week therapy and 24-week therapy (P=0.82). The most 
      common adverse effects (AEs) were: anemia 32% (n=64/202), infections 26% 
      (n=38/149), neutropenia 23% (n=35/149), thrombocytopenia 21% (n=32/149) and renal 
      failure 8% (n=12/149). CONCLUSION: SOF+DCV+/-RBV regimen is of high efficacy and 
      tolerability in LT recipients with HCV infection.
CI  - Copyright (c) 2016 Elsevier Masson SAS. All rights reserved.
FAU - Liao, Haotian
AU  - Liao H
AD  - Department of Liver Surgery, Liver Transplantation Division, West China Hospital, 
      Sichuan University, Chengdu 610041, China.
FAU - Tan, Ping
AU  - Tan P
AD  - Department of Urology, Institute of Urology, West China Hospital, Sichuan 
      University, Chengdu 610041, China.
FAU - Zhu, Zexin
AU  - Zhu Z
AD  - Department of Liver Surgery, Liver Transplantation Division, West China Hospital, 
      Sichuan University, Chengdu 610041, China.
FAU - Yan, Xiaokai
AU  - Yan X
AD  - Department of Liver Surgery, Liver Transplantation Division, West China Hospital, 
      Sichuan University, Chengdu 610041, China.
FAU - Huang, Jiwei
AU  - Huang J
AD  - Department of Liver Surgery, Liver Transplantation Division, West China Hospital, 
      Sichuan University, Chengdu 610041, China. Electronic address: 
      HuangjiweiMD@foxmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20170109
PL  - France
TA  - Clin Res Hepatol Gastroenterol
JT  - Clinics and research in hepatology and gastroenterology
JID - 101553659
RN  - 0 (Antiviral Agents)
RN  - 0 (Carbamates)
RN  - 0 (Imidazoles)
RN  - 0 (Pyrrolidines)
RN  - 49717AWG6K (Ribavirin)
RN  - HG18B9YRS7 (Valine)
RN  - LI2427F9CI (daclatasvir)
RN  - WJ6CA3ZU8B (Sofosbuvir)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Carbamates
MH  - Drug Therapy, Combination
MH  - Genotype
MH  - Hepatitis C/*drug therapy
MH  - Humans
MH  - Imidazoles/*therapeutic use
MH  - *Liver Transplantation
MH  - Pyrrolidines
MH  - Ribavirin/therapeutic use
MH  - Sofosbuvir/*therapeutic use
MH  - Treatment Outcome
MH  - Valine/analogs & derivatives
EDAT- 2017/01/14 06:00
MHDA- 2018/04/10 06:00
CRDT- 2017/01/14 06:00
PHST- 2016/09/10 00:00 [received]
PHST- 2016/11/23 00:00 [revised]
PHST- 2016/12/06 00:00 [accepted]
PHST- 2017/01/14 06:00 [pubmed]
PHST- 2018/04/10 06:00 [medline]
PHST- 2017/01/14 06:00 [entrez]
AID - S2210-7401(16)30207-8 [pii]
AID - 10.1016/j.clinre.2016.12.001 [doi]
PST - ppublish
SO  - Clin Res Hepatol Gastroenterol. 2017 Jun;41(3):262-271. doi: 
      10.1016/j.clinre.2016.12.001. Epub 2017 Jan 9.